OxyContin Will Face Fewer Generics Following Patent Infringement Settlement
This article was originally published in The Pink Sheet Daily
Executive Summary
As part of settlement agreements with Purdue Pharma, Endo and Teva agree to stop selling generic versions of the pain medication.
You may also be interested in...
OxyContin Patent Settlement Could Mean No Generics Come 2008
Purdue reaches agreement with final generic manufacturer of extended-release oxycodone.
OxyContin Patent Settlement Could Mean No Generics Come 2008
Purdue reaches agreement with final generic manufacturer of extended-release oxycodone.
Endo To Launch Opana ER Oxymorphone With Two Risk Management Programs
The firm will add 220 sales reps to support the July launch of the extended-release and immediate-release opioid analgesics.